Cirrus Therapeutics
Cirrus Therapeutics is a privately held biotech company specializing in ocular immunology. The company is pioneering innovative cell and gene therapies to treat age-related macular degeneration (AMD) and other chronic blinding diseases. Their lead program features a novel adeno-associated virus (AAV) gene therapy aimed at restoring IRAK-M, a crucial immune regulator in retinal cells, to combat dry AMD and preserve vision. Cirrus Therapeutics is committed to advancing ocular health and improving the quality of life for patients as they age.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $11M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $11M
- Latest Funding Round
- Seed Round
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Seed Round | $11.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| ClavystBio | Seed Round |
| Polaris Partners | Seed Round |
| SEEDS | Seed Round |
Similar Companies
A snapshot of private companies similar to Cirrus Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
